Content overview: “FDA Flags Safety Signal After Four Deaths in Schizophrenia Drug Trial; Argenx Setback and ”. The FDA has identified a potential safety signal after four patient deaths occurred in a clinical trial for an investigational schizophrenia drug, raising concerns about the treatment's risk profile. The agency is reviewing the data, though it has not disclosed the drug's name or the trial's phase. This development underscores the challenges in developing new therapies for schizophrenia, a condition with significant unmet need.
In other news, Argenx faced an unusual setback, though details were not specified in the source. Meanwhile, Eli Lilly has filed lawsuits against sellers of copycat versions of its obesity drug, aiming to protect its market share amid soaring demand for weight-loss medications. These legal actions highlight the intense competition and regulatory complexities in the booming obesity drug market. The full version stays on the original page, which this listing opens directly.